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a-Interferon therapy normalizes aminotransferase levels in approximately 50°/,, of the patients with chronic hepatitis C, 
but post-therapy relapses are common and predictive factors of sustained response remain largely unknown. We retrospec- 
tively assessed several parameters as predictors of sustained remission after a 12-month course of lymphoblastoid tx- 
interferon: the Knodell histological activity index, serum levels of procollagen type III peptide, serum HCV-RNA, anti- 
a-interferon antibodies, and anti-HCV antibodies (C-100-3), all at month 12. Thirty-seven patients were studied. Fourteen 
patients were non-responders (38%), 15 patients experienced a sustained response (40.5%) and eight patients responded 
similarly but relapsed after a-interferon withdrawal (21.5°/,,). A decrease in the histological activity index above 5, nor- 
malization of procollagen type III peptide levels (<12 ng/ml) and the absence of viremia after treatment were all signifi- 
cantly associated with a sustained response (p=0.008, p=0.007 and p=0.037, respectively). Anti-interferon antibodies 
were detected in only one non-responder patient. Anti-C-100-3 antibodies became undetectable at month 12 in 5 of the 
15 sustained responders. The best prediction of sustained response was obtained from the three variables independent of
multivariate analysis according to the following equation: F=0.872+0.067×K (decrease of histological index) -0.052×P 
(procollagen type III peptide levels at month 12) -0.28×R (HCV-RNA at month 12; R=2 when present and R= 1 when 
absent). A score higher than 0 predicted sustained remission with a 100°/,, sensitivity and specificity in this series of 
patients. The results of this study may be useful in establishing the optimal duration of a-interferon therapy. © Journal 
of Hepatology. 
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Although chronic hepatitis C may follow a mild and 
asymptomatic course, it may also lead to cirrhosis and 
hepatocellular carcinoma in a substantial proportion of 
patients (1,2). At present, a-interferon is the only therapy 
which has shown promising results for this disease. Dur- 
ing a-interferon treatment, aminotransferase levels be- 
come normal and the hepatic necroinflammatory lesion 
improves in approximately 50% of patients (3-6). How- 
ever, relapse of liver disease after discontinuation of treat- 
ment has been reported in about 50% of the responders 
in most trials (3), and it has been suggested that only sus- 
tained responders may obtain long-term benefit from a- 
interferon therapy (7-9). Some preliminary results have 
suggested that a longer duration of a-interferon treatment 
could enhance sustained remission rates (6). Factors 
which could predict post-therapy outcome (sustained re- 
sponse or disease relapse) remain largely unknown (10). 
However, preliminary studies have shown that clearance 
of serum hepatitis C virus (HCV) RNA accompanies the 
biochemical response to a-interferon in most cases, and 
that relapse of the disease is preceded by the reappearance 
of viremia (11,12). 
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Predictive parameters of relapse would allow treatment 
to be tailored for each patient, thus improving clinical 
results and the cost-benefit ratio. Accordingly, the aim of 
this study was to assess everal parameters etrospectively 
as predictors of post-therapy relapse, in a series of chronic 
hepatitis C patients consecutively treated with a 12-month 
course of lymphoblastoid a-interferon. 
Patients and Methods 
Patients 
Thirty-seven consecutive patients with chronic hepatitis 
C treated with a 12-month course of a-interferon were 
included in this study. Lymphoblastoid a-interferon 
(Wellferon ®, Wellcome, Beckenham, UK) was adminis- 
tered in a step-down schedule: 3 million units (MU) daily 
for 2 months, 3 MU three times per week for 3 months, 
and 1.5 MU three times per week for 7 months. The mean 
follow up after completion of therapy was 40.7_+8.3 
months (range: 30-53). The patients had been entered 
into an open randomized controlled trial of lymphoblast- 
oid a-interferon treatment versus no therapy, as described 
in detail elsewhere (6). All patients had had elevated 
aminotransferase levels for at least 6 months before start- 
ing therapy. Diagnosis of chronic hepatitis C was estab- 
lished by the presence of anti-HCV antibodies (C-100-3) 
(Ortho Diagnostic Systems, Raritan, N J) after exclusion 
of other conditions by appropriate laboratory tests 
(HBsAg, autoantibodies, al-antitrypsin, ceruloplasmin, 
urinary copper, serum iron and ferritin). None of the pa- 
tients had received hepatotoxic drugs or had consumed 
alcohol for at least 6 months before starting therapy. Pa- 
tients with clinically decompensated cirrhosis, systemic 
diseases, and anti-human immunodeficiency virus anti- 
bodies were not entered into the trial. All patients gave 
written informed consent prior to entry into the trial, and 
the study was approved by the Local Ethics Committee. 
Aminotransferase levels were assessed monthly during the 
entire follow-up period. Three groups of patients were de- 
fined according to the response to therapy; the non-re- 
sponse group included all patients with elevated alanine 
aminotransferase (ALT) levels at the end of therapy, the 
sustained-response group included all patients with nor- 
mal ALT values at the end of therapy, and which per- 
sisted within the normal range during post-therapy follow 
up, and the relapse group included all patients with nor- 
mal ALT levels at the end of therapy but who experienced 
an elevation of ALT values after a-interferon withdrawal. 
Liver histology 
Pretreatment liver biopsies were obtained uring the 3 
months before therapy began and post-treatment liver 
specimens were obtained uring the last 2 weeks of ther- 
apy. The overall histological diagnosis was made accord- 
ing to standard criteria (13). All patients had chronic ac- 
tive hepatitis or active cirrhosis. Liver specimens were 
formalin-fixed and paraffin-embedded. Four-/.tm-thick 
sections tained with hematoxylin and eosin, Masson tri- 
chrome, periodic acid Schiff with previous diastase diges- 
tion and a reticulin stain were used for histological grad- 
ing. A single experienced liver pathologist examined all 
the liver biopsies under code and applied the histological 
scoring system described by Knodell et al. (14) to pre- 
treatment and post-treatment liver specimens from all pa- 
tients. 
Serum procollagen type III peptide 
Serum procollagen type III aminoterminal peptide (PII- 
IP) levels were determined before and at the end of ther- 
apy using a commercial radioimmunoassay kit (RIA 
gnost PIIIP; Behringwerke AG, Marburg, Germany). 
Serum samples were stored at -40°C until assay. 
Serum HCV RNA 
The presence of HCV RNA in serum was studied by 
the reverse transcription "nested" polymerase chain reac- 
tion (PCR) in a sample obtained immediately before start- 
ing therapy and in a sample collected at the time of the 
second liver biopsy. In addition, serum samples from sus- 
tained responders were assessed for the presence of HCV 
RNA at months 6 and 12 after a-interferon withdrawal. 
The PCR primer sequences were derived from the highly 
conserved 5' noncoding region of the HCV genome (15) 
(Outer primers; C15 sense: 5'GTATCTCGAGGCGA- 
CACTCCACCATAGAT3' and C16 antisense: 5'AT- 
ACTCGAGGTGCACGGTCTACGAGACCT3'. Inner 
primers; C17 sense: 5'CCACCATAGATCTCTCCCCT- 
GT3' and C18 antisense: 5'CACTCTCGAGCACCCTA- 
TCAGGCAGT3'). The PCR was perfot'rned as described 
elsewhere (16), and false positive results were carefully 
avoided applying the recommended measures (17). 
Anti-lymphoblastoid a-interferon antibodies 
Neutralizing anti-lymphoblastoid a-interferon anti- 
bodies were studied by a bioassay in a serum sample 
collected uring the last week of therapy. This bioassay 
is based on the protective ffect of lymphoblastoid a- 
interferon on monkey kidney V3 cells challenged with 
Semliki Forest virus (18). Purified lymphoblastoid a-in- 
terferon of a standardized potency and control antisera 
(kindly supplied by Wellcome Research Foundation) 
were used to confirm the specificity and sensitivity of the 
assay. 
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Anti-HCV antibodies 
Samples from each patient obtained before and at the 
end of therapy were tested for the presence of antibodies 
to HCV (C-100-3) using a commercial first-generation e - 
zyme-linked immunoassay (ELISA) (Ortho Diagnostic 
Systems, Raritan, N J). 
Statistics 
Student's t-test was used for continuous variables and 
Fisher's exact test for dichotomous variables. ANOVA 
was used for comparing the three groups. The Mann- 
Whitney U-test was applied to non-parametric values (de- 
crease of the Knodell 's histological activity index and sub- 
indices). Multivariate analysis (stepwise logistic-re- 
gression) was applied to all factors in order to obtain a 
discriminant function which could improve the prediction 
of sustained remission (19). Statistical significance was de- 
fined as a p-value of 0.05 or less and all p-values are two- 
tailed. The SPSS/PC+statistical package was used for the 
analysis. Results are presented as means_+SD, unless 
otherwise specified. 
Results 
Table 1 shows the characteristics of each group of pa- 
tients and Fig. 1 shows the ALT profile in the three 
groups. Fourteen patients (38%) did not respond to ther- 
apy (non-response group), 15 patients (40.5%) experi- 
enced a sustained response during treatment without re- 
lapsing during a mean follow up of 41 _+8 months (range: 
30-53) after therapy (sustained-response group), and 
eight patients (21.5%) showed a similar complete response 
during therapy, but relapsed after a-interferon with- 
drawal (follow up: 42_+8 months; range: 30-51) (relapse 
group). The eight post-therapy relapses occurred 1-2 
months after the completion of the treatment, and later 
rebounds were not observed. 
Histological activity index 
Table 2 shows changes in the histological activity index 
in the sustained-response and relapse groups. Before ther- 
apy, the histological activity index in the sustained-re- 
sponse group was significantly higher than that of the re- 
lapse group (11.80_+2.93 vs. 8.87_+3.22; p=0.048). 
However, at the end of the treatment there were no sig- 
nificant differences between the two groups (5.60_+2.69 vs. 
6.12_+2.64). The mean decrease in the histological activity 
index in the sustained-response group was significantly 
higher than in the relapse group (6.20_+2.88 vs 2.75_+1.58; 
p=0.008). The mean decrease in the relapse and non-re- 
sponse groups was similar (2.75_+1.58 vs. 2.93_+2.70). The 
decrease in the histological activity index in the sustained- 
response group was caused by a marked improvement of 
the periportal and lobular inflammation (Table 2). How- 
ever, the periportal index was the only one which de- 
creased significantly more in the sustained-response group 
TABLE 1 
Characteristics of patients at base line 
Characteristic Non-response group Sustained-response group Relapse group p* 
n=14 n=15 n=8 
Age (yr) 48.2± 14.6 35.5--- 12.2 44.2± 15.31 NS 
Sex (M/F) 10/4 10/5 4/4 NS 
Acute hepatitis 4/14 7/15 4/8 NS 
Estimated uration of disease (years) 3.8±2.1 4.1 +-3.3 5.9±4.2 NS 
Source of hepatitis: 
a) transfusions 2 7 2 
b) drug addiction - 5 - 
c) other parenteral 1 1 2 
d) unknown I 1 2 4 
Histology: 
chronic hepatitis/cirrhosis 9/5 13/2 5/3 NS 
Analytical data: 
AST (U/I) ~** 85.4___43.4 119.1 ±84.6 127.9± 132.0 NS 
ALt (Ufl) b** 143.2___ 60.6 222.0--- 163.6 160.1 ± 161.1 NS 
Alkaline phosphatase (U/I) c** 156.9___67.2 134.1 -.+46.8 152.7± 38.6 NS 
yGT (U/l) d** 42.9±39.7 49.2±35.7 47.6±34.4 NS 
Bilirubin (mg/dl) 0.98___0.36 1.00±0.43 0.77±0.16 NS 
Albumin (g/dl) 4.17+--0.37 4.37±0.55 4.27±0.31 NS 
Gammaglobulins (g/dl) 1.42+0.39 1.53---0.30 1.37±0.32 NS 
Prothrombin i dex (%)c** 87.7± 14.8 85.4 + - 10.1 87.7± 12.3 NS 
Anti-HCV antibodies 14/14 15/15 8/8 NS 
* Statistical differences between sustained-response and relapse groups. 
** Normal ranges; a0-25 U/l, b 0-29 U/l, c 73-207 U/l, d 5-38 U/l, ~ 75-120%. 
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Fig. I. Changes in alanine aminotransferase (ALT) levels in the non- 
response, sustained-response and relapse groups. ALT levels are pre- 
sented as means±SEM. 
than in the relapse group (2.60+_1.45 vs. 0.88+_1.13; p= 
0.009). It was observed that a decrease in the histological 
activity index higher than or equal to 5 predicted a sus- 
tained remission after therapy with a sensitivity of 73% 
and a specificity of 87.5% (positive predictive value: 92%, 
negative predictive value: 64%). 
Procollagen type 111 aminoterminal peptide levels 
Base line PI I IP levels were similar in the three groups 
of patients (non-response: 16.9---4.7, sustained-response: 
17.7+_4.5, relapse: 15.5+_4.2), However, as shown in Fig. 
2, at month 12 significant differences were observed be- 
tween the sustained-response and the relapse groups 
(10.9_+2.4 vs. 14.4+_2.7; p=0.007), and between the sus- 
tained-response and the non-response groups (10.9+_2.4 
vs. 17.4+_4.6; p<0.001). Differences between the relapse 
and the non-response groups were not statistically sig- 
nificant. PI I IP concentrations reached the normal range 
(6-12 ng/ml) at the end of therapy in 73% of the sus- 
tained-responder patients, while it occurred in only 25% 
and 14% of the patients from the relapse and non-re- 
sponse groups (p=0.037 and p=0.002, respectively). The 
normalization of PI I IP levels predicted a sustained post- 
therapy remission of  the disease with a sensitivity of 73% 
and a specificity of 75% (positive predictive value: 85%, 
negative predictive value: 60%). 
Serum HCV RNA 
Figure 3 shows changes in the detection of viremia in 
the three groups of patients. Before treatment, detection 
rates of HCV RNA were similar in the three groups (non- 
response: 78%, sustained-response: 85%, r.elapse: 87%). In 
contrast, at the end of the a-interferon course significant 
differences were observed between the sustained-response 
and the relapse groups, and between the sustained-re- 
sponse and non-response groups. No differences were 
found between the relapse and the non-response groups. 
Seventy-three per cent of the patients who had a sus- 
tained-response were not viremic at the end of the ther- 
apy, as compared to only 25% and 7% of the cases from 
the relapse and non-response groups respectively (p= 
0.037 and p<0.001). Accordingly, the estimated sensi- 
tivity and specificity of serum HCV RNA to predict a 
sustained response was 73% and 75%, respectively, for a 
TABLE 2 
Changes of the Knodell histological activity indexes in the sustained-response and relapse groups 
Sustained-response group Relapse group 
n= 15 n=8 
Base line End of Mean Base line End of Mean 
therapy decrease therapy decrease 
Periportal 3.46"-- 1.40 0.86±0.95 2.60± 1.45 "** 1.87"-, 1.16 1.00±0.86 0.88__ + 1.13" 
Lobular 2.73"-,1.12 0.73±0.77 2.00± 1.31 b 1.75±0.96 0.62±0.48 1.12±1.05 b 
Portal 3.53±0.49 2.46±0.95 1.06---0.99 ¢ 3.37±0.48 2.62±0.99 0.75±0.82 ¢ 
Fibrosis 2.06--.I.06 1.53±0.95 0.53-+0.95 ~ 1.87__+1.16 1.87±1.16 0 J 
Total 11.80__.2.93' 5.60±2.69 6.20±2.88' 8.87---3.22 6.12±2.64 2.75± 1.58 + 
** Statistical differences between the two groups with respect to the mean decreases of each one of the histological scores: ~ p<0.01, bNS, c NS, 
'J NS, c p<0.01. 
* p<0.05 versus base line total histological activity index of the relapse group. 
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Fig. 2. Procollagen type III peptide (PIIIP) concentrations at the end 
of the therapy (month 12) in the three groups of patients. Significant 
differences may be observed between the sustained-response andre- 
lapse groups, and between the sustained-response andnon-response 
groups. The shaded area represents he normal range of PIIIP levels. 
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Fig. 3. Changes in the detection of serum HCV RNA (before ther- 
apy/end of therapy) in the three groups of patients. A significant 
decrease may be observed only in the sustained-response group. 
positive predictive value of 85% and a negative predictive 
value of 60%. However, sustained remission was attained 
in four patients who had viremia at the time of a-inter- 
feron withdrawal. Further follow up of these patients 
showed disappearance of HCV RNA in three patients at 
months 6 and 12, while one patient who had moderately 
active cirrhosis before therapy remained viremic at 
months 6, 12 and 24 after the completion of treatment, 
despite persistently normal ALT levels assessed at 
monthly intervals. A liver biopsy of this patient obtained 
1 year after finishing therapy showed mildly active cir- 
rhosis. The remaining II patients who had a sustained 
response and had cleared HCV RNA from sera remained 
without detectable viremia at months 6 and 12 after the 
end of the a-interferon course. Thus, post-therapy follow 
up showed that 93% (14/15) of  the sustained responders 
cleared serum HCV RNA. 
Neutralizing anti-lymphoblastoid a-intezferon antibodies 
Anti-lymphoblastoid a-interferon antibodies were de- 
tected at the end of therapy in only one non-responder 
patient, thus precluding any association between its pres- 
ence and the post-therapy evolution of the disease. 
Anti-HCV antibodies 
Antibodies to the C-100-3 recombinant antigen of HCV 
became negative in five patients (33'70) from the sustained- 
response group at the end of therapy. In contrast, none 
of the relapsers and non-responders lost anti-C-100-3 
antibodies (positive predictive value: 100%, negative pre- 
dictive value: 44%). 
Muhivariate analysis 
In order to obtain a discriminant function, forward 
stepwise logistic-regression analysis was applied to all 
variables. Decrease of the histological activity index, and 
PI I IP levels and the presence or absence of HCV RNA, 
both at the end of therapy, were independently predictive 
and allowed to obtain the following equation: F=0.872+ 
0.067 K-0.052 P-0.28 R, where K corresponds to 
the histological activity index at base line minus the histo- 
logical activity index at month 12, P to PI I IP levels in ng/ 
ml at month 12, and R to HCV RNA at month 12 (a 
PCR positive result=2 and a PCR negative result= 1). All 
sustained-responders had an F higher than 0 while all re- 
lapsers had an F of less than 0 for a sensitivity and speci- 
ficity of 100%. 
Discussion 
Until now, most reports on a-interferon treatment of 
chronic hepatitis C have focussed on the short-term utility 
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of this therapy, i.e. in the normalization of aminotransfer- 
ase levels during administration. However, the goal of a- 
interferon therapy should be the induction of a sustained 
remission of the disease or even a complete recovery of 
the process. Some studies have shown that a-interferon 
suppresses HCV replication in most patients who experi- 
ence a biochemical response to therapy, as measured by 
the detection of HCV RNA in serum with the PCR tech- 
nique (6,11,12). However, in most trials post-treatment 
relapses affected approximately 50% of the patients who 
had experienced a biochemical response during therapy 
(3). Therefore, disappearance of HCV RNA from sera 
during therapy does not preclude further reactivation of 
the disease when a-interferon is discontinued, which is 
probably due to low-level replication of HCV within the 
liver or in other sites such as peripheral blood mono- 
nuclear cells (20). Future studies hould compare the pres- 
ence of HCV RNA in serum and liver tissue before, dur- 
ing and after a-interferon therapy. In accordance with 
this series in which relapses occurred during the first 2 
months after a-interferon withdrawal, other studies have 
shown that the vast majority of relapses take place during 
the early post-therapy period (6 months) (7,8). However, 
late relapses (>12 months after stopping therapy) have 
also been observed (21). 
In agreement with a previous uncontrolled study (7,22) 
we found a high rate of sustained remissions (40% of the 
treated patients) in the present study. 
Study of the liver biopsies howed that the post-therapy 
outcome of the disease was more related to the degree of 
liver inflammation i the pretreatment biopsy than to that 
observed in the biopsy obtained at the end of the therapy. 
However, the variable more strongly associated with post- 
therapy outcome was the mean decrease in the histologi- 
cal activity index. In the sustained-response group the de- 
crease in the histological activity index was significantly 
higher than that in the relapse group. Differences were 
mainly due to a higher degree of pretreatment periportal 
and lobular damage in sustained responders, although the 
histological activity index was also lower at the end of 
therapy in these patients. 
These observations might suggest hat periportal and 
lobular inflammation could reflect he involvement of the 
immune system in the clearance of hepatocytes infected 
with HCV, as has been documented in chronic hepatitis 
B (23). Other studies also have suggested the implication 
of the immune system in liver damage in chronic hepatitis 
C (24-26). Hence, although a-interferon seems to have a 
direct antiviral effect in HCV infection, a competent im- 
mune system is probably a prerequisite for achieving sus- 
tained remission or eradication of the infection. In sup- 
port of this view, among patients undergoing liver 
transplantation for end-stage HCV-related liver disease, 
a-interferon seems less efficacious in suppressing HCV 
replication (27). In any case, our findings show that long- 
term response isassociated with a marked histological im- 
provement due to a better esponse to IFN. 
Procollagen III peptide levels have been related to the 
extent of liver fibrosis and inflammatory activity, prob- 
ably reflecting liver fibrogenesis and fibrolysis (28,29). 
Thus, the higher degree of periportal and lobular in- 
flammation at baseline in the sustained-response group 
compared to the relapse group could explain the trend 
towards higher PIIIP levels in sustained responders. Most 
sustained responders (73%) attained normalization of PII- 
IP levels at the end of therapy, compared to only 25% of 
those who relapsed. This may indicate a more profound 
effect of a-interferon i suppressing viral replication and 
inflammation in patients who experience a sustained re- 
mission of the disease. Thus, measurement of PIIIP values 
at the end of a-interferon treatment might help predict 
post-therapy outcome. Similar results have been observed 
in a recent study (8). 
The PCR technique used in this study detected viremia 
in most patients before a-interferon therapy. However, 
although the sustained-response and relapse groups 
showed a similar biochemical response to tz-interferon, vi- 
remia was detected at the end of therapy in most patients 
who relapsed, despite normal aminotransferase levels dur- 
ing the treatment period. In contrast, most sustained-re- 
sponders cleared HCV RNA. One study (11) showed that 
HCV RNA was cleared from serum in all the biochemical 
responder patients at weeks 1 or 2 after starting a 4- to 8- 
week course of a- or fl-interferon therapy. In this short- 
term trial, the absence of viremia at the end of therapy 
was unrelated to post-treatment outcome. Recently, 
serum HCV RNA at the end of therapy was found to be 
predictive of post-therapy outcome (30,31). In the present 
study the presence of viremia was significantly associated 
with post-therapy relapse. However, two patients who did 
not have detectable viremia at the end of therapy still re- 
lapsed, and even more striking, four patients in whom 
HCV RNA was detected at the time of the completion of 
the a-interferon course experienced a long-term sustained 
response. In three of these cases, HCV RNA was not de- 
tected at months 6 and 12 after finishing therapy. The 
fourth case had detectable viremia at months 6, 12 and 
24 after therapy, in spite of having normal ALT values in 
monthly assessments. Thus, "residual" or low-level repli- 
cation of HCV, might not preclude long-term remission 
of chronic hepatitis C. Further studies are needed to clar- 
ify whether healthy carriers exist or whether a smoldering 
hepatic disease persists in x, iremic patients with normal 
ALT.values, as suggested by the presence of periportal 
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inflammation 1 year after finishing therapy in one case in 
our study with persistent serum HCV RNA and also by 
one study of blood donors with confirmed anti-HCV anti- 
bodies and persistently normal ALT levels (32). However, 
another study indicates that persistent viremia may be 
found in individuals with normal histology and normal 
aminotransferase values (33). 
Anti-lymphoblastoid a-interferon antibodies were de- 
tected in only one patient, which supports another study 
showing a very low rate of development of neutralizing 
antibodies (1.2%) when using lymphoblastoid a-inter- 
feron preparations (34). Our observation that one third 
of long-term responders lost anti-C-100-3 antibodies has 
been also reported by others (7,35). Other antibodies, 
such as those directed to the core protein, however, tend 
to persist in most treated patients (36). 
Since the decrease of the histological activity index, PII- 
IP levels and viremia by the end of therapy were indepen- 
dent of the prediction of sustained remission on multivari- 
ate analysis, we obtained a linear discriminant function 
which had a 100% sensitivity and specificity in this series 
of patients. This function, however, needs to be prospect- 
ively assessed in a clinical trial and might not be useful 
with other interferon schedules. If a second liver biopsy 
cannot be performed, sustained remission could be pre- 
dicted on the basis of PII IP levels and serum HCV RNA. 
Normalization of PII IP levels and/or clearance of HCV 
RNA at the end of therapy predicted sustained remission 
with a positive predictive value of 82.5% and a negative 
predictive value of 83%. 
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